[go: up one dir, main page]

SG11201602070TA - Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease - Google Patents

Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Info

Publication number
SG11201602070TA
SG11201602070TA SG11201602070TA SG11201602070TA SG11201602070TA SG 11201602070T A SG11201602070T A SG 11201602070TA SG 11201602070T A SG11201602070T A SG 11201602070TA SG 11201602070T A SG11201602070T A SG 11201602070TA SG 11201602070T A SG11201602070T A SG 11201602070TA
Authority
SG
Singapore
Prior art keywords
nicotinimide
btk
inflammation
inhibitors
cancer
Prior art date
Application number
SG11201602070TA
Other languages
English (en)
Inventor
Xiangyang Chen
Yingxiang Gao
Chong Liu
Haihong Ni
Mark Mulvihill
Original Assignee
Beijing Synercare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Synercare Pharma Tech Co Ltd filed Critical Beijing Synercare Pharma Tech Co Ltd
Publication of SG11201602070TA publication Critical patent/SG11201602070TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201602070TA 2013-09-30 2014-09-29 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease SG11201602070TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884958P 2013-09-30 2013-09-30
CN201310485048 2013-10-16
PCT/US2014/058084 WO2015048662A2 (en) 2013-09-30 2014-09-29 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Publications (1)

Publication Number Publication Date
SG11201602070TA true SG11201602070TA (en) 2016-04-28

Family

ID=52497918

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602070TA SG11201602070TA (en) 2013-09-30 2014-09-29 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Country Status (16)

Country Link
US (6) US9951056B2 (el)
EP (1) EP3052476B1 (el)
JP (1) JP6615752B2 (el)
KR (1) KR102272792B1 (el)
CN (1) CN104341388B (el)
AU (1) AU2014324595B2 (el)
CA (1) CA2925624C (el)
CY (1) CY1123388T1 (el)
MX (1) MX2016004030A (el)
PL (1) PL3052476T3 (el)
RS (1) RS60934B1 (el)
RU (1) RU2677884C2 (el)
SG (1) SG11201602070TA (el)
SI (1) SI3052476T1 (el)
SM (1) SMT202000549T1 (el)
WO (1) WO2015048662A2 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951056B2 (en) 2013-09-30 2018-04-24 Beijing Innocare Pharma Tech Co., Ltd. Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX2016005054A (es) * 2013-10-21 2016-07-19 Merck Patent Gmbh Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos.
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2016094628A1 (en) * 2014-12-11 2016-06-16 Merck Patent Gmbh Assays for btk inhibitors
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
EP3782994B1 (en) 2015-12-16 2025-07-16 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
EP3459940B8 (en) * 2016-05-16 2022-08-24 Evopoint Biosciences Co., Ltd. 5-aminopyrazole carboxamide derivative as btk inhibitor and preparation method and pharmaceutical composition thereof
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107646855B (zh) * 2017-08-02 2020-07-07 浙江工业大学 一种含哌啶噻唑类化合物在制备杀菌剂中的应用及其制备方法
CA3077238C (en) * 2017-09-28 2022-04-12 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
BR112020004126A2 (pt) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited conjugado anticorpo-derivado de pirrolbenzodiazepina
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
WO2019213545A1 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
MX2021003064A (es) * 2018-09-18 2021-05-27 Beijing Innocare Pharma Tech Co Ltd Formas cristalinas de 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifeni l)nicotinamida.
CN110964016B (zh) 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
PE20211053A1 (es) 2018-10-05 2021-06-07 Forma Therapeutics Inc Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30)
KR20210090201A (ko) * 2018-11-06 2021-07-19 베이징 이노케어 파마 테크 씨오., 엘티디. 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드를 포함하는 무정형 고체 분산액
EP3880675B1 (en) 2018-11-12 2024-11-06 Debiopharm International SA Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3122183A1 (en) * 2018-12-13 2020-06-18 Intervet International B.V. Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide
WO2020173407A1 (en) 2019-02-25 2020-09-03 Beijing Innocare Pharma Tech Co., Ltd. Process for preparing 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
CN112334469B (zh) * 2019-03-18 2022-10-04 上海海雁医药科技有限公司 Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113563305B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(n-取代氧基羰基哌啶-4-)基烟酰胺的制备方法
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
CN114085207B (zh) * 2020-10-16 2024-06-25 广州百霆医药科技有限公司 布鲁顿酪氨酸蛋白激酶抑制剂及其应用
CN114957242B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
CN114853752B (zh) * 2021-02-03 2023-08-22 药雅科技(上海)有限公司 Btk抑制剂吡啶并杂环类化合物的制备及其应用
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
JP2024522588A (ja) * 2021-06-08 2024-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗がん化合物
EP4342892A4 (en) * 2021-07-01 2025-04-30 Hangzhou Healzen Therapeutics Co., Ltd. Bruton's tyrosine kinase and mutant degrader, composition and application thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114920844B (zh) * 2022-06-27 2023-12-29 上海润诺生物科技有限公司 一种增强car-t功能的合成纳米抗体及其制备方法和应用
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法
CN118063429B (zh) * 2022-11-23 2025-02-25 天津瑞程健达医药科技有限公司 作为btk抑制剂的吡啶酰胺类化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CA2601628C (en) * 2005-03-10 2014-05-13 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2007117692A2 (en) * 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
HUE029095T2 (en) 2006-09-22 2017-02-28 Pharmacyclics Llc BRUTON tyrosine kinase inhibitors
NZ579911A (en) * 2007-03-28 2012-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
MX357627B (es) * 2008-06-27 2018-07-17 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
JP2013538227A (ja) * 2010-09-17 2013-10-10 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン化合物およびその使用
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
BR112013030442B1 (pt) * 2011-06-10 2021-11-09 Merck Patent Gmbh Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112015002590A2 (pt) * 2012-08-10 2019-08-06 Boehringer Ingelheim Int compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk)
KR101668574B1 (ko) * 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
PE20151495A1 (es) * 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
MX367918B (es) * 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
JP6509838B2 (ja) * 2013-06-26 2019-05-08 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
US9951056B2 (en) * 2013-09-30 2018-04-24 Beijing Innocare Pharma Tech Co., Ltd. Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX2016005054A (es) * 2013-10-21 2016-07-19 Merck Patent Gmbh Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos.

Also Published As

Publication number Publication date
AU2014324595A1 (en) 2016-04-07
EP3052476A4 (en) 2017-03-29
US20180222897A1 (en) 2018-08-09
WO2015048662A2 (en) 2015-04-02
US20220298153A1 (en) 2022-09-22
KR102272792B1 (ko) 2021-07-05
KR20160058188A (ko) 2016-05-24
US20250059176A1 (en) 2025-02-20
US20190276446A1 (en) 2019-09-12
CN104341388B (zh) 2017-03-22
WO2015048662A3 (en) 2015-05-07
US9951056B2 (en) 2018-04-24
US11840513B2 (en) 2023-12-12
CA2925624C (en) 2021-06-15
CY1123388T1 (el) 2021-12-31
US10301297B2 (en) 2019-05-28
RU2016115803A (ru) 2017-11-09
US20160237075A1 (en) 2016-08-18
US12162873B2 (en) 2024-12-10
US11345695B2 (en) 2022-05-31
US20240101545A1 (en) 2024-03-28
CN104341388A (zh) 2015-02-11
RU2016115803A3 (el) 2018-05-16
RS60934B1 (sr) 2020-11-30
CA2925624A1 (en) 2015-04-02
JP2016531893A (ja) 2016-10-13
SMT202000549T1 (it) 2020-11-10
PL3052476T3 (pl) 2021-01-11
MX2016004030A (es) 2016-10-26
HK1207063A1 (en) 2016-01-22
EP3052476B1 (en) 2020-07-15
SI3052476T1 (sl) 2020-12-31
JP6615752B2 (ja) 2019-12-04
EP3052476A2 (en) 2016-08-10
RU2677884C2 (ru) 2019-01-22
AU2014324595B2 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SG11201602070TA (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
EP2964022A4 (en) ANALGIC COMBINATION AND USE
GB201320729D0 (en) Therapeutic compounds and their use
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
SG11201509259RA (en) Bispecific constructs and their use in the treatment of various diseases
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
GB201311361D0 (en) Compounds and their therapeutic use
IL244901A0 (en) Derivatives of aminotetralin and aminoindan, pharmaceutical compositions containing them and their use in therapy
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
EP2969008A4 (en) MEDICATION FOR THE TREATMENT OF CANCER, CARDIOVASCULAR DISEASES AND INFLAMMATION
GB201308736D0 (en) Compounds and their therapeutic use
IL244435A0 (en) Fidotimide for use in the treatment of diseases associated with inflammation
GB201308753D0 (en) Compounds and their use in therapy
LT3052476T (lt) Pakeisti nikotinimido btk inhibitoriai ir jų preparatai bei naudojimas vėžio, uždegimo ir autoimuninės ligos gydymui
GB201308217D0 (en) Compounds and their use in therapy
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
GB201312131D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy
TH1401007652A (th) อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน
GB201317804D0 (en) Therapeutic compounds and their use